|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 19/06 | |
| C07H 19/16 | |||
| C07H 19/14 | |||
| A61K 31/7064 | |||
| A61K 31/7076 | |||
| A61P 31/12 |
| (11) | Number of the document | 1633766 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04775900.6 |
| Date of filing the European patent application | 2004-04-21 | |
| (97) | Date of publication of the European application | 2006-03-15 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2004/012472 |
| Date | 2004-04-21 |
| (87) | Number | WO 2005/003147 |
| Date | 2005-01-13 |
| (30) | Number | Date | Country code |
| 474368 P | 2003-05-30 | US |
| (72) |
CLARK, Jeremy, US
|
| (73) |
Gilead Pharmasset LLC,
c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404,
US
|
| (54) | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |
| MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |